NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast announced a quarterly dividend on Friday, June 15th. Shareholders of record on Friday, June 29th will be paid a dividend of $0.48 per share on Wednesday, August 8th. This represents a $1.92 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, June 28th. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) posted its earnings results on Thursday, August, 2nd. The specialty retailer reported $1.16 EPS for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.18. The specialty retailer earned $117.30 million during the quarter, compared to the consensus estimate of $101.75 million. Medifast had a return on equity of 37.25% and a net margin of 10.87%. The business's revenue for the quarter was up 55.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Medifast.

Medifast updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $4.35-4.45 for the period, compared to the Thomson Reuters consensus estimate of $3.67. The company issued revenue guidance of $460-470 million, compared to the consensus revenue estimate of $398.16 million.Medifast also updated its Q3 guidance to $1.05-1.10 EPS.

2 Wall Street analysts have issued 1-year target prices for Medifast's shares. Their forecasts range from $55.00 to $249.00. On average, they expect Medifast's stock price to reach $152.00 in the next twelve months. This suggests that the stock has a possible downside of 28.0%. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Some companies that are related to Medifast include MCCORMICK & Co/SH SH NV (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Media headlines about MED stock have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medifast earned a media and rumor sentiment score of 0.48 on Accern's scale. They also assigned news coverage about the specialty retailer an impact score of 46.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Medifast.

Medifast's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.90%), Renaissance Technologies LLC (8.31%), Dimensional Fund Advisors LP (5.79%), Acadian Asset Management LLC (3.76%), Bank of New York Mellon Corp (1.44%) and American Century Companies Inc. (1.20%). Company insiders that own Medifast stock include Charles P Connolly, Glenn W Welling, Jeffrey J Brown, Jeremy John Martin, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, American Century Companies Inc., Martingale Asset Management L P, Castleark Management LLC, EAM Investors LLC, ClariVest Asset Management LLC, TD Asset Management Inc. and Bessemer Group Inc.. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Glenn W Welling, Jeremy John Martin, Michael C Macdonald and Ralph Rushton. View Insider Buying and Selling for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Intrinsic Edge Capital Management LLC, MUFG Securities EMEA plc, BlackRock Inc., Point72 Asset Management L.P., Russell Investments Group Ltd., Osterweis Capital Management Inc., Navellier & Associates Inc and BNP Paribas Arbitrage SA. Company insiders that have bought Medifast stock in the last two years include Glenn W Welling, Jeffrey J Brown and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $211.10.

Medifast has a market capitalization of $2.45 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]